Malabsorption Syndrome Market Research Report– Global Forecast till 2027

Malabsorption Syndrome Market Trends And Share Analysis By Diagnosis (Tests, Imaging), Causative Diseases (Lactose Intolerance, Sprue, Cystic Fibrosis), Treatment (Gluten-Free Diet, Antidiarrheal Agents, Anti-Inflammatory Drugs), End User – Global Forecast Till 2027

ID: MRFR/Pharma/4014-HCR | February 2021 | Region: Global | 85 pages

Malabsorption Syndrome Market Overview


The malabsorption syndrome market is anticipated to grow substantially in the years to come. The pharmacy computerization systems market value is expected to grow at a CAGR (Compound Annual Growth Rate) of about 11% by 2023. Unmet medical demands, growing government support, rising healthcare spending in developed nations, improved regulatory framework, increasing adoption rate, and rising financing and reimbursement policies are all contributing to the malabsorption syndrome market growth.


Malabsorption syndrome is characterized by insufficient absorption of lipids, vitamins, carbohydrates, protein, and other nutrients from the intestine into the circulation. Prolonged antibiotic usage, Celiac disease, cystic fibrosis, Crohn's disease, lactose intolerance, parasite illnesses, gallbladder or liver disease, and intestinal inflammation are all potential causes of malabsorption syndrome.


Growing incidences of cause disorders like celiac disease and others are cited as a major reason fueling the malabsorption syndrome industry. According to the Celiac Disease Foundation, celiac disease is a dangerous autoimmune illness that affects one in every 100 persons globally.


Covid-19 Analysis


With the rise of the Covid-19 impact, many large-scale businesses and industries suffered, except healthcare and life support products. The lockdown and physical distancing protocols have affected millions of small and big business institutions alike. Pharmaceutical and biotech businesses, along with governments across the globe, are collaborating to handle the Covid-19 epidemic, from vaccine research to planning for pharmaceutical supply chain issues.


Approximately 115 vaccine candidates and 155 compounds are now in the R&D pathway. Furthermore, routinely used medications such as hydroxychloroquine have shown a huge increase in demand for Covid-19 control. Because of the enormous demand for these treatments, makers of Covid-19 management pharmaceuticals have a lot of chances, since many wealthy nations are running out of them. As a result of the demand for Covid-19 vaccines and treatment medications, the pharmaceutical & biotechnology sectors are predicted to increase significantly in the future. This, in turn, is likely to have a major influence on the global market for malabsorption syndrome.


Market Dynamics


Drivers


The increasing number of cases of causative diseases like celiac disease and others are expected to fuel the growth of the malabsorption syndrome market share. Increased prevalence of digestive diseases and associated illnesses will drive the market expansion. Likewise, the increased financial support rendered for researchers to explore innovative interventions and an increased rate of certain cancers where radiation therapy is used as the primary treatment will propel the market growth.


Opportunities


Growing healthcare costs in developed nations, as well as an enhanced regulatory environment, are likely to create more potential for the malabsorption syndrome market value to rise. Moreover, the key players of the market are adopting various R&D initiatives and industry trends such as product launches to fuel market expansion.


Restraints


Some factors are predicted to hinder the market share expansion. The absence of a healthcare budget in several middle-income countries, a shortage of trained workforce and severe safety standards, and the failures of clinical trials during the development phase are among the primary issues limiting the market growth.


Challenges


The absence of healthcare resources in some low-income countries, an inadequately trained staff, and strict safety regulations may act as factors that slow down the market growth. This will further challenge the malabsorption syndrome market over the forecast years.


Cumulative Growth Analysis


The malabsorption syndrome market is anticipated to grow substantially in the years to come. The pharmacy computerization systems market value is expected to grow at a CAGR of about 11%. Unmet medical demands, growing government support, rising healthcare spending in developed nations, improved regulatory framework, increasing adoption rate, and rising financing and reimbursement policies are all contributing to the malabsorption syndrome market growth.


Value Chain Analysis


Malabsorption syndrome refers to a group of digestive illnesses where the small intestine is unable to absorb nutrients, vitamins, or minerals from the digestive system into circulation. Malabsorption syndrome has also been linked to several illnesses, including digestive issues, chronic antibiotic usage, and surgery. It can also be caused by a lack of digestive enzyme synthesis. People suffering from malabsorption experience fatigue, weight loss, or gastrointestinal discomfort.


A rise in the number of gastrointestinal issues and other diseases will boost malabsorption syndrome market growth. Moreover, large financial assistance to researchers for creating newer interventions, and an increase in the incidence of certain cancers where radiation therapy is used as the primary treatment are some of the key factors driving the growth of the market value. Also, the increase in market investments in R&D, as well as partnerships for product development, would provide new possibilities for during the market forecast.


Segment Overview


The global malabsorption syndrome market is classified into many segments, such as causative diseases, diagnosis, treatment, and end-user. Listed below are the malabsorption disorder market segments:


By causative diseases



  • Cystic fibrosis

  • Parasitic diseases

  • Intestinal disorders


    • Celiac disease

    • Others


  • Lactose intolerance

  • Whipple’s disease

  • Tropical sprue

  • Others


By diagnosis



  • Imaging studies


    • Ct scan

    • Endoscopic retrograde cholangiopancreatogram (ERCP)

    • Magnetic resonance cholangiopancreatography (MRCP)

    • Abdominal x-ray


  • Hematologic tests

  • Other tests


    • Test of fat malabsorption

    • Tests of carbohydrate absorption

    • Schilling test

    • D-xylose test

    • Test of bile salt absorption

    • C-d-xylose breath test



By treatment 



  • Gluten-free diet

  • Anti-inflammatory drugs

  • Antibiotics

  • Nutritional supplements

  • Protease and lipase supplements

  • Antidiarrheal agents

  • Others


By end-user



  • Hospitals

  • Academic and Research Institutes

  • Pharmaceutical companies

  • Nutrition Clinics

  • Others


Regional Analysis


The malabsorption syndrome market analysis division comprises North America, Europe, Asia Pacific, and the rest of the world. Because of increased rates of causative disorders such as lactose intolerance, cystic fibrosis, diarrhea, and others, along with high health expenditures, the Americas lead the market. Adults and children suffering from cystic fibrosis are at risk of developing decreased bone density and accompanying problems owing to nutritional loss. 


Europe is the second-largest market for malabsorption syndrome. The government's support towards research and development, and its attempts to enhance reimbursement systems in healthcare are also projected to boost the European market. Due to a large patient population and improving healthcare technologies, estimated To be the fastest growing market. Healthcare spending is also rising in many Asia Pacific countries. As per the Australian Institute of Health and Welfare, overall health spending in Australia in 2015 was around USD 170.4 billion. Due to inadequate technical expertise and inadequate medical facilities, the Middle East and Africa have the smallest proportion of the Malabsorption Syndrome Market.


Competitive Landscape


The malabsorption syndrome industry is dominated by a few companies that play a vital role in the market growth. These malabsorption disorder equipment provider companies are called key companies of the market. They contribute to the largest share of the market profit.


The companies account for the market profits by adopting various malabsorption syndrome market trends such as joint ventures, product launches, company expansions, and procurements.


Key Players


Below are the key companies that malabsorption syndrome diagnosis & treatment equipment in the global market:



  • Abbvie Inc.

  • AstraZeneca PLC

  • DSM

  • Gilead Sciences

  • Glenmark Pharmaceuticals

  • Lupin Pharmaceuticals Inc.

  • McNeil Nutritionals

  • Perrigo

  • Roche

  • Vetbiochem India Private Limited

  • Actelion Pharmaceuticals Ltd

  • Bayer Healthcare AG

  • Eli Lily and Company

  • GlaxoSmithKline plc.

  • KLAIRE LABORATORIES

  • Mallinckrodt Pharmaceuticals

  • National Enzyme Company

  • Pfizer Inc.

  • Sanofi


Recent Developments 



  • Many of the key players of the market are adopting various initiatives such as product launches, advancements in equipment technology, and others. Moreover, they are investing a lot in the research and development of the market.


Report Overview 


This report delivers all the information about the global malabsorption syndrome market size in the forecast period. It also contains different sections of the market analysis to help obtain detailed information such as opportunities, challenges, drivers, Covid-19 analysis, regional analysis, competitive landscape, and others. Moreover, all the information is collected from verified primary and secondary sources to provide the expected market outlook.


Geographically



  • Europe

  • Asia-Pacific

  • North America

  • Middle East & Africa

  • Rest of the world



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   11.0% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Causative Diseases, Treatment and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors    Abbvie, Inc., Actelion Pharmaceuticals Ltd, AstraZeneca PLC, Bayer Healthcare AG, DSM, Eli Lily and Company, Gilead Sciences, GlaxoSmithKline plc, Glenmark Pharmaceuticals, KLAIRE LABORATORIES, Lupin Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, McNeil Nutritionals, National Enzyme Company, Perrigo, Pfizer, Inc., Roche, Sanofi, Vetbiochem India Private Limited
  Key Market Opportunities   Rising healthcare expenditure in the developed countries and improving regulatory framework
  Key Market Drivers   Rising cases of causative diseases such as celiac disease, and others


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


malabsorption syndrome market is projected to grow at an 11.0% CAGR between 2020-2027.

The Americas is expected to dominate the malabsorption syndrome market.

Rising healthcare expenditure and favorite reimbursement policies are the key factors adding to the malabsorption syndrome market growth.

Poor healthcare system and certain side effects may limit the malabsorption syndrome market growth.

Major end users of the malabsorption syndrome market include academic and research institutes, nutrition clinics, hospitals, pharmaceutical companies, and others.

Table of Contents:


Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Malabsorption Syndrome Market, by Diagnosis

6.1 Introduction

6.2 Hematologic Tests

6.2.1 Market Estimates & Forecast, 2020 – 2027

6.3 Imaging Studies

6.3.1 Market Estimates & Forecast, 2020 – 2027

6.4 Other Tests

6.4.1 Market Estimates & Forecast, 2020 – 2027

Chapter 7. Global Malabsorption Syndrome Market, by Causative Diseases

7.1 Introduction

7.2 Lactose Intolerance

7.2.1 Market Estimates & Forecast, 2020 – 2027

7.3 Cystic Fibrosis

7.3.1 Market Estimates & Forecast, 2020 – 2027

7.4 Whipple’s Disease

7.4.1 Market Estimates & Forecast, 2020 – 2027

7.5 Parasitic Diseases

7.5.1 Market Estimates & Forecast, 2020 – 2027

7.6 Tropical sprue

7.6.1 Market Estimates & Forecast, 2020 – 2027

7.7 Intestinal Disorders

7.7.1 Market Estimates & Forecast, 2020 – 2027

7.8 Others

7.8.1 Market Estimates & Forecast, 2020 – 2027

Chapter 8. Global Malabsorption Syndrome Market, by Treatment

8.1 Introduction

8.2 Nutritional Supplements

8.2.1 Market Estimates & Forecast, 2020 – 2027

8.3 Gluten-Free Diet

8.3.1 Market Estimates & Forecast, 2020 – 2027

8.4 Protease and Lipase Supplements

8.4.1 Market Estimates & Forecast, 2020 – 2027

8.5 Antibiotics

8.5.1 Market Estimates & Forecast, 2020 – 2027

8.6 Antidiarrheal Agents

8.6.1 Market Estimates & Forecast, 2020 – 2027

8.7 Anti-Inflammatory Drugs

8.7.1 Market Estimates & Forecast, 2020 – 2027

Chapter 9. Global Malabsorption Syndrome Market, by End User

9.1 Introduction

9.2 Pharmaceutical Companies

9.2.1 Market Estimates & Forecast, 2020 – 2027

9.3 Hospitals

9.3.1 Market Estimates & Forecast, 2020 – 2027

9.4 Nutrition Clinics

9.4.1 Market Estimates & Forecast, 2020 – 2027

9.5 Academic and Research Institutes

9.5.1 Market Estimates & Forecast, 2020 – 2027

9.6 Academic and Research Institutes

9.6.1 Market Estimates & Forecast, 2020 – 2027

Chapter 10. Global Malabsorption Syndrome Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Abbvie, Inc.

12.1.1 Company Overview

12.1.2 Diagnosis of Causative Agents Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Actelion Pharmaceuticals Ltd

12.2.1 Company Overview

12.2.2 Diagnosis of Causative Agents Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 AstraZeneca PLC

12.3.1 Company Overview

12.3.2 Diagnosis of Causative Agents Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 Bayer Healthcare AG

12.4.1 Company Overview

12.4.2 Diagnosis of Causative Agents/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 DSM

12.5.1 Company Overview

12.5.2 Diagnosis of Causative Agents Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 ELI LILY AND COMPANY

12.6.1 Company Overview

12.6.2 Diagnosis of Causative Agents Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Gilead Sciences

12.7.1 Overview

12.7.2 Diagnosis of Causative Agents Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Malabsorption Syndrome Industry

Chapter 14 Appendix

LIST OF TABLES

Table 1 Malabsorption Syndrome Industry Synopsis, 2020 – 2027

Table 2 Malabsorption Syndrome Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Malabsorption Syndrome Market by Region, 2020 – 2027, (USD Million)

Table 4 Malabsorption Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 5 Malabsorption Syndrome Market by Causative Diseases, 2020 – 2027, (USD Million)

Table 6 Malabsorption Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 7 Malabsorption Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 8 North America Malabsorption Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 9 North America Malabsorption Syndrome Market by Causative Diseases, 2020 – 2027, (USD Million)

Table 10 North America Malabsorption Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 11 North America Malabsorption Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 12 US Malabsorption Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 13 US Malabsorption Syndrome Market by Causative Diseases, 2020 – 2027, (USD Million)

Table 14 US Malabsorption Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 15 US Malabsorption Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 16 Canada Malabsorption Syndrome market by Diagnosis, 2020 – 2027, (USD Million)

Table 17 Canada Malabsorption Syndrome Market by Causative Diseases, 2020 – 2027, (USD Million)

Table 18 Canada Malabsorption Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 19 Canada Malabsorption Syndrome market by End User, 2020 – 2027, (USD Million)

Table 20 South America Malabsorption Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 21 South America Malabsorption Syndrome Market by Causative Diseases, 2020 – 2027, (USD Million)

Table 22 South America Malabsorption Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 23 South America Malabsorption Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 24 Europe Malabsorption Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 25 Europe Malabsorption Syndrome Market by Causative Diseases, 2020 – 2027, (USD Million)

Table 26 Europe Malabsorption Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Europe Malabsorption Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 28 Western Europe Malabsorption Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 29 Western Europe Malabsorption Syndrome Market by Causative Diseases, 2020 – 2027, (USD Million)

Table 30 Western Europe Malabsorption Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 31 Western Europe Malabsorption Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 32 Eastern Europe Malabsorption Syndrome market by Diagnosis, 2020 – 2027, (USD Million)

Table 33 Eastern Europe Malabsorption Syndrome Market by Causative Diseases, 2020 – 2027, (USD Million)

Table 34 Eastern Europe Malabsorption Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 35 Eastern Europe Malabsorption Syndrome Market by End User, 2020 – 2027, (USD Million)

Table 36 Asia Pacific Malabsorption Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 37 Asia Pacific Malabsorption Syndrome Market by Causative Diseases, 2020 – 2027, (USD Million)

Table 38 Asia Pacific Malabsorption Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 39 Asia Pacific Malabsorption Syndrome market by End User, 2020 – 2027, (USD Million)

Table 40 The Middle East & Africa Malabsorption Syndrome Market by Diagnosis, 2020 – 2027, (USD Million)

Table 41 The Middle East & Africa Malabsorption Syndrome Market by Causative Diseases, 2020 – 2027, (USD Million)

Table 42 The Middle East & Africa Malabsorption Syndrome Market by Treatment, 2020 – 2027, (USD Million)

Table 43 The Middle East & Africa Malabsorption Syndrome market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Malabsorption Syndrome Market

Figure 3 Segmentation Market Dynamics for Malabsorption Syndrome Market

Figure 4 Global Malabsorption Syndrome market Share, by Diagnosis 2020

Figure 5 Global Malabsorption Syndrome market Share, by Causative Diseases 2020

Figure 6 Global Malabsorption Syndrome market Share, by Treatment 2020

Figure 7 Global Malabsorption Syndrome market Share, by End User, 2020

Figure 8 Global Malabsorption Syndrome market Share, by Region, 2020

Figure 9 North America Malabsorption Syndrome market Share, by Country, 2020

Figure 10 Europe Malabsorption Syndrome market Share, by Country, 2020

Figure 11 Asia Pacific Malabsorption Syndrome market Share, by Country, 2020

Figure 12 Middle East & Africa Malabsorption Syndrome market Share, by Country, 2020

Figure 13 Global Malabsorption Syndrome market: Company Share Analysis, 2020 (%)

Figure 14 Abbvie, Inc.: Key Financials

Figure 15 Abbvie, Inc.: Segmental Revenue

Figure 16 Abbvie, Inc.: Geographical Revenue

Figure 17 Actelion Pharmaceuticals Ltd: Key Financials

Figure 18 Actelion Pharmaceuticals Ltd: Segmental Revenue

Figure 19 Actelion Pharmaceuticals Ltd: Geographical Revenue

Figure 20 AstraZeneca PLC: Key Financials

Figure 21 AstraZeneca PLC: Segmental Revenue

Figure 22 AstraZeneca PLC: Geographical Revenue

Figure 23 Bayer Healthcare AG: Key Financials

Figure 24 Bayer Healthcare AG: Segmental Revenue

Figure 25 Bayer Healthcare AG: Geographical Revenue

Figure 26 DSM: Key Financials

Figure 27 DSM: Segmental Revenue

Figure 28 DSM: Geographical Revenue

Figure 29 ELI LILY AND COMPANY: Key Financials

Figure 30 ELI LILY AND COMPANY: Segmental Revenue

Figure 31 ELI LILY AND COMPANY: Geographical Revenue

Figure 32 Gilead Sciences: Key Financials

Figure 33 Gilead Sciences: Segmental Revenue

Figure 34 Gilead Sciences: Geographical Revenue